Dermatology Equity Rollover in PE Deals Explained
Dermatology equity rollover is a feature of many private equity transactions in which the selling physician reinvests part of the sale proceeds into the buyer’s platform. Instead of receiving the entire purchase price in cash, the seller receives cash for part of the practice and an ownership stake in the larger company for the rest.
Rollover equity can create a second opportunity for value if the platform grows and is later sold. It also carries risk, because that value is not certain. This guide explains how rollover generally works and what sellers should consider. Deal terms vary widely, and nothing here is legal, tax or investment advice. Sellers should work with healthcare counsel, accountants and financial advisors.
Why Buyers Ask Sellers to Roll Equity
Private equity groups often ask selling physicians to retain a stake for several reasons:
- Alignment: sellers who own part of the platform have an incentive to help it grow
- Retention: physicians with an ownership stake may be more likely to stay through the transition
- Deal financing: rolled equity reduces the cash the buyer must fund at closing
- Shared upside: both sides benefit if the platform is later sold at a higher value
Our article on dermatology private equity covers the broader decision of whether to sell.
How Dermatology Equity Rollover Works
In a typical deal, the buyer agrees to a purchase price for the practice. A portion is paid in cash at closing, and the seller reinvests the remainder into equity of the platform or a holding company. The rollover percentage is negotiated and can vary considerably from deal to deal.
The seller then holds units or shares in an entity they do not control. Their eventual return depends on the platform’s performance, the debt it carries, the terms of the equity and the timing and price of any future sale.
What Determines the Value of Rollover Equity
Several factors influence what rollover equity may eventually be worth:
- Platform performance: growth in earnings across all practices in the group
- Leverage: debt at the platform level is generally repaid before equity holders
- Equity class: whether the seller’s equity has the same rights as the investors’ equity or sits behind preferred returns
- Dilution: future acquisitions and capital raises may reduce the seller’s percentage
- Exit timing: when and at what value the platform is eventually sold
Because practice earnings drive both the initial price and the platform’s later value, understanding how earnings are measured matters. Our guide to dermatology practice EBITDA explains the basics.
Key Terms to Review
The equity documents may be as important as the purchase agreement. Sellers should ask counsel to review:
- The class of equity received and its rights compared with the investors’ equity
- Any preferred return or liquidation preference ahead of the seller’s equity
- Vesting, forfeiture or repurchase provisions if the physician leaves early
- Drag-along and tag-along rights in a future sale
- Information rights, so the seller can follow platform performance
- Restrictions on transferring the equity
Some agreements allow the company to repurchase equity at a reduced value if a physician departs under certain conditions. Understanding these provisions before signing is essential.
Risks of Rollover Equity
Rollover equity is an investment, and its value may rise, fall or be lost. Sellers should consider:
- Concentration of personal wealth in a single, illiquid holding
- Limited control over decisions that affect value
- Uncertain timing of any second sale
- The effect of platform debt on equity value
- Post-sale compensation that may be lower than prior owner income
Comparing an offer with a higher rollover percentage against one with more cash at closing can help clarify how much risk you are willing to take.
Tax Considerations
Rollover structures can have significant tax implications, and whether part of a rollover may be tax-deferred depends on how the transaction is structured. An experienced accountant and tax attorney should review the structure before signing. Our article on dermatology practice sale taxes outlines topics sellers commonly discuss with their advisors.
Questions to Ask Before Agreeing to a Rollover
- What percentage of the price is cash, and what percentage is rolled?
- What class of equity will I receive, and what sits ahead of it?
- How much debt does the platform carry, and how might that change?
- What happens to my equity if I leave, retire or become disabled?
- What information will I receive about platform performance?
- What is the investors’ expected holding period?
An independent advisor can help you evaluate the answers. US Medical Funding’s advisory and consulting services can help owners think through valuation and exit options.
Alternatives to a Rollover
Owners who prefer more certainty may consider physician buyers, associate succession or a dermatology partner buyout, where the practice stays independent and sellers are paid through a financed transaction. These options typically provide more cash at closing and no ongoing equity exposure, though the total price and terms may differ. Preparation helps whichever path you choose; see our article on how to prepare a dermatology practice for sale.
Final Thoughts
Dermatology equity rollover can offer upside, but it shifts part of the sale price from cash today to an uncertain future payout. Understanding how rollover equity is valued, which rights it carries and how much risk you are comfortable holding can help you compare offers and make a decision that fits your goals.
US Medical Funding helps dermatologists and their buyers finance practice transitions, including independent alternatives to a private equity sale. Learn more about our dermatology practice financing options.
